iBio
IBIO
32 hedge funds and large institutions have $2.96M invested in iBio in 2025 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
21% more capital invested
Capital invested by funds: $2.44M → $2.96M (+$511K)
7% more funds holding
Funds holding: 30 → 32 (+2)
1.59% less ownership
Funds ownership: 19.75% → 18.16% (-1.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$371K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$101K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$100K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$34.2K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$30K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
-$371K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$22K |
| 3 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$21.4K |
| 4 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
-$15.2K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$287 |
IBIO Hedge Fund Activity: Q3 2025 in Review
32 of the 7,622 institutional investors tracked by Wall St. Rank reported a position in iBio (IBIO) for Q3 2025, worth a combined $2.96M — up 21% from $2.44M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new IBIO positions and 3 closed out — a net gain of 3 holders — while 8 added to existing stakes and 6 trimmed.
The largest buyer was Ameriprise, opening a new position worth an estimated $371K. The largest seller was Lynx1 Capital Management, cutting an estimated $371K.
- 32 institutional investors held iBio (IBIO) as of Q3 2025, up from 30 in Q2 2025.
- Funds reported $2.96M of iBio stock for Q3 2025, up 21% quarter-over-quarter.
- 6 funds opened new iBio positions in Q3 2025 and 3 closed out, a net change of +3 holders.
- The largest iBio buyer in Q3 2025 was Ameriprise, an estimated $371K added.
- The largest iBio seller in Q3 2025 was Lynx1 Capital Management, an estimated $371K sold.
Based on aggregated 13F filings for Q3 2025.